China's Sinopharm has already rolled out its first batch of COVID-19 vaccines to COVAX, a global initiative aimed to make doses more accessible to poorer countries. Now, the company is in talks to expand supplies. What are the company's production plans for the future? Will it be challenging for China National Biotec Group (CNBG) to guarantee supplies domestically while making supplies for COVAX? CGTN's Liu Yang spoke to one of the Sinopharm executives to find these answers.